Excellent study addressing an important problem in a small subgroup of women (AGC on Pap cytology). It demonstrates the high rate of HPV-positivity in AIS and endocervical adenocarcinoma (100% in this series), clearly separating the latter from endometrial carcinoma (0%). It also shows that more squamous lesions (HSIL and cancer) are found from AGC cytology than AIS or adenocarcinoma.
The comments with respect to endometrial cancer that would be missed by primary HPV testing (3%), in which HPV-negative cytology would not be investigated or even followed up, are appropriate. Cervical screening is not aimed at detecting endometrial carcinoma, which requires other strategies.
However, cervical screening is designed to detect HSIL and squamous cell carcinoma. My only criticism of this article is that insufficient attention is paid to the 3% with HPV-negative HSIL and squamous cell carcinoma, which are rather more relevant than the same percentage of endometrial carcinomas. This at least deserves a mention -and is interesting in the context of this small subset of women. HPV-negativity of squamous lesions is a serious consideration for primary HPV testing -3% were found in this small subset of women by 'co-testing' which would be missed -the authors should mention its relevance to the possibly slightly higher percentage in the screening population at large.
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GENERAL COMMENTS
This objective of the study is clear and the results can lead to an improvement of the management of atypical glandular cells (AGC).
The authors demonstrate that in the context of an HPV primary screening where the AGC will be found after an HPV positive result only, the PPV will be around 60%, largely better than compared to the one with unknow HPV status . Furthermore it suggests that in the context of a cytology primary screening, the management of AGC should be the triage with an HPV test before sending the patients to colposcopy.
Five endometrial cancers and one metastasis were found as many as adenocarcinoma of the cervix in this population. These endometrial adenocarcinoma were diagnosed only in the group of women of more than 50 years and HPV negative. 
The subject matter is interesting. However, the manuscript is poorly written and disorganized due to language issues. The sentences are not entirely coherent. It is difficult for the reader to understand the meaning of the statements. Thus, it was very difficult to evaluate the science. The authors will need to reformat the English before resubmitting the paper for scientific review. Excellent study addressing an important problem in a small subgroup of women (AGC on Pap cytology). It demonstrates the high rate of HPV-positivity in AIS and endocervical adenocarcinoma (100% in this series), clearly separating the latter from endometrial carcinoma (0%). It also shows that more squamous lesions (HSIL and cancer) are found from AGC cytology than AIS or adenocarcinoma. ***We thank the reviewer for this highly supportive comment. The comments with respect to endometrial cancer that would be missed by primary HPV testing (3%), in which HPV-negative cytology would not be investigated or even followed up, are appropriate. Cervical screening is not aimed at detecting endometrial carcinoma, which requires other strategies. ***We thank the reviewer for this highly supportive comment. However, cervical screening is designed to detect HSIL and squamous cell carcinoma. My only criticism of this article is that insufficient attention is paid to the 3% with HPV-negative HSIL and squamous cell carcinoma, which are rather more relevant than the same percentage of endometrial carcinomas. This at least deserves a mention -and is interesting in the context of this small subset of women. HPV-negativity of squamous lesions is a serious consideration for primary HPV testing -3% were found in this small subset of women by 'co-testing' which would be missed -the authors should mention its relevance to the possibly slightly higher percentage in the screening population at large. ***A comment on this has been inserted in the discussion.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 2 Reviewer Name: Christine Bergeron Institution and Country: Laboratory Cerba 95066 Cergy Pontoise Cedex 9, France Competing Interests: None declared Comment: This objective of the study is clear and the results can lead to an improvement of the management of atypical glandular cells (AGC). The authors demonstrate that in the context of an HPV primary screening where the AGC will be found after an HPV positive result only, the PPV will be around 60%, largely better than compared to the one with unknown HPV status . Furthermore it suggests that in the context of a cytology primary screening, the management of AGC should be the triage with an HPV test before sending the patients to colposcopy. ***We thank the reviewer for this highly supportive comment.
Comment: Five endometrial cancers and one metastasis were found as many as adenocarcinoma of the cervix in this population. These endometrial adenocarcinoma were diagnosed only in the group of women of more than 50 years and HPV negative. These findings cannot be ignored and similar findings have been published yet. Endometrial cancer is usually diagnosed after bleeding by an endometrial biopsy Protocols should evaluate if the cotesting for women of more than 50 years could benefit for a group of women at risk to have an endometrial cancer.
***Indeed, the issue of what to do with the endometrial cancers that may be detected when screening for cervical cancer is difficult. Please note that reviewer 1 thought that we had discussed this issue adequately. We have further expanded on this discussion.
Minor suggestions p6 the authors give 0.3% of AGC reported in Sweden. It looks high and is usually less than 0.1% of the general population and less than 5% of the abnormal smears. The authors do not differentiate the sub-groups proposed in the Bethesda Terminology 2001: Atypical glandular cells (AGC) of the endocervix, endometrium, or glandular not otherwise specified (NOS) and Atypical glandular cells, favor neoplastic; can they do subanalysis in these groups and in the group of cytologic adenocarcinoma in situ (AIS) in the same population? ***We have inserted a comment describing that Sweden uses the diagnostic criteria of the Bethesda terminology except for the subgroups of AGC that are not used. Comment: The subject matter is interesting. However, the manuscript is poorly written and disorganized due to language issues. The sentences are not entirely coherent. It is difficult for the reader to understand the meaning of the statements. Thus, it was very difficult to evaluate the science. The authors will need to reformat the English before resubmitting the paper for scientific review. ***As described above, the paper has been edited to increase clarity and has had a language review by a native American. 
GENERAL COMMENTS
Some editing is needed -numbers under 10 should be spelt out except for numerical values. Abstract Participants -cervical 'smear' -this should be 'sample' as the use of LBC is explained later on. Conclusion -'implies safety of primary HPV screening strategies'. Please add '……with regard to this subset of patients'.
Discussion
Thank you for adding something about HPV primary screening programs but doesn't quite reflect what I said. "Only 3% of the HSIL lesions detected after AGC would be missed by not referring HPV-negative AGC' should be followed by '….although this percentage may not reflect HPV-negative lesions in screening tests as a whole'. 'Some programs are contemplating…… after HPV-negative AGC' is somewhat repetitive without addling '….. along with others without AGC. I say this because the 3% figure could be extrapolated to programs recommending HPV testing on its own -i.e. Australia and the UK. 
REVIEWER

VERSION 2 -AUTHOR RESPONSE
We have revised the manuscript in accordance with the comments of the reviewers and hope that the manuscript will now meet with your acceptance.
